SCHEMBL4417403

SCHEMBL4417403

O=C(O)c1oc2ccncc2c1Nc1cc(F)c(I)cc1F

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAP2K1 Q02750 4/20 0.56
BRAF P15056 6/20 0.36
EIF2AK3 Q9NZJ5 5/20 0.36
IDO1 P14902 4/20 0.34
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
MAPK1 P28482 1/20 0.33
KMT2A Q03164 1/20 0.33
MAP2K2 P36507 1/20 0.33
TDO2 P48775 3/20 0.32
ALDH1A1 P00352 1/20 0.32
HPGD P15428 1/20 0.32
CSNK2A1 P68400 1/20 0.31
RXFP1 Q9HBX9 1/20 0.31
TP53 P04637 1/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2566005 0.87 MAP2K1 (0.72) MAP2K1IDO1MAP2K2
SCHEMBL2565576 0.85 MAP2K1 (0.53) MAP2K1BRAFEIF2AK3KDM4EALDH1A1
SCHEMBL4417407 0.83 MAP2K1 (0.56) MAP2K1BRAFEIF2AK3IDO1KDM4E
SCHEMBL2563035 0.82 MAP2K1 (0.56) MAP2K1IDO1TDO2ALDH1A1HPGD
SCHEMBL12164550 0.81 MAP2K1 (0.72) MAP2K1MAP2K2
SCHEMBL4989997 0.81 MAP2K1 (0.59) MAP2K1BRAFEIF2AK3IDO1KDM4E
SCHEMBL5010174 0.80 MAP2K1 (0.56) MAP2K1BRAFEIF2AK3KDM4EMEN1
SCHEMBL4979784 0.80 MAP2K1 (0.54) MAP2K1BRAFEIF2AK3IDO1KDM4E
SCHEMBL4986447 0.80 MAP2K1 (0.54) MAP2K1BRAFEIF2AK3IDO1MAP2K2
SCHEMBL2565034 0.80 MAP2K1 (0.81) MAP2K1BRAFMAPK1MAP2K2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2069354-A1 AZA-BENZOFURANYL COMPOUNDS AND METHODS OF USE Genentech, Inc. (US) 2009-06-17 EP disclosed
US-20080085886-A1 Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide GENENTECH, INC. 2008-04-10 US disclosed
WO-2008024725-A1 AZA-BENZOFURANYL COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085886-A1 Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide MAP3K2, MAP3K1, MAP2K2 MAP2K1 10/4885BRAF 42/4885EIF2AK3 463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.